🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
7.04
-0.20 (-2.76%)
At close: Nov 20, 2026, 4:00 PM EST
7.03
-0.01 (-0.14%)
After-hours: Nov 20, 2026, 7:30 PM EST

Company Description

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.

Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC.

The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Evommune, Inc.
Evommune logo
CountryUnited States
Founded2020
IPO DateNov 6, 2025
IndustryBiotechnology
SectorHealthcare
Employees48
CEOLuis Pena

Contact Details

Address:
1891 Page Mill Road
Palo Alto, California 94304
United States
Phone(925) 247-4481
Websiteevommune.com

Stock Details

Ticker SymbolEVMN
ExchangeNYSE
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code2044725
CUSIP Number30054Y107
ISIN NumberUS30054Y1073
Employer ID85-0742575
SIC Code2834

Key Executives

NamePosition
Luis C. PenaFounder, President, Chief Executive Officer and Director
Kyle Carver CPA, M.B.A.Chief Financial Officer
Gregory S. Moss Esq.Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer
Dr. Eugene Andrew Bauer M.D.Co-Founder, Chief Medical Officer and Director
Dr. Jeegar Patel Ph.D.Chief Scientific Officer
Janice Drew M.P.H.Chief of Development Operations
Dr. Lou Sehl Ph.D.Senior Vice President of Technical Operations
Dr. Daniel J. Burge M.d.Senior Vice President of Clinical Development
J. Mark Jackson M.D.Senior Vice President of Clinical Development

Latest SEC Filings

DateTypeTitle
Nov 17, 2026424B3Prospectus
Nov 17, 20268-KCurrent Report
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 12, 2026424B3Prospectus
Nov 12, 202610-QQuarterly Report
Nov 12, 20268-KCurrent Report
Nov 10, 2026SCHEDULE 13D/AFiling
Nov 5, 20268-KCurrent Report
Nov 4, 2026424B3Prospectus
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides